第二代药物洗脱支架在左主干冠心病患者中的安全性与有效性
本研究基于3项前瞻性注册研究汇总的2692例接受第二代药物洗脱支架(DES)治疗的左主干冠心病(LMCAD)患者,比较四种DES的3年靶血管失败率。结果显示不同DES间靶血管失败率无显著差异(p=0.15),但PtCr-EES较BP-BES的靶血管失败风险更高(HR 1.60,95%CI 1.01-2.54,p=0.046)。
要点
- 第二代DES治疗LMCAD的3年靶血管失败率无显著组间差异。
- PtCr-EES较BP-BES的靶血管失败风险显著升高(HR 1.60)。
- 所有DES的3年支架血栓发生率均较低(≤1.0%),总体上EES平台更优。
核心结论
- 在左主干冠心病患者中,不同第二代DES的3年靶血管失败风险无显著差异,但PtCr-EES较BP-BES的靶血管失败风险更高。
研究设计与样本
- 汇总3项前瞻性注册研究(IRIS-DES、IRIS-MAIN、PRECOMBAT),纳入2007年7月至2015年7月间2692例接受第二代DES的显著LMCAD患者。
主要发现
- 3年靶血管失败率:CoCr-EES 16.7%,BP-BES 13.2%,PtCr-EES 18.7%,Re-ZES 14.7%(p=0.15)。
- 多治疗倾向评分分析中,PtCr-EES较BP-BES的靶血管失败调整HR为1.60(95%CI 1.01-2.54,p=0.046)。
- 全因死亡、任何心肌梗死或任何血运重建的复合终点及其各组分风险在不同DES间无显著差异。
- 所有DES的3年支架血栓发生率均≤1.0%,组间差异总体倾向于EES平台。
临床怎么用
- 在左主干冠心病介入治疗中,第二代DES整体安全有效,选择时需注意PtCr-EES较BP-BES靶血管失败风险更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data are available on the relative performances between different types of drug-eluting stents (DES) for obstructive left main coronary artery disease (LMCAD). OBJECTIVES: This study sought to compare effectiveness and safety profiles of various second-generation DES for LMCAD in real-world clinical practice. METHODS: Among 4,470 patients in 3, multicenter, prospective registries (IRIS-DES [Interventional Cardiology Research Incorporation Society-Drug-Eluting Stents] registry, the IRIS-MAIN [Interventional Cardiology Research Incorporation Society-Left MAIN Revascularization] registry, and the PRECOMBAT [PREmier of Randomized COMparison of Bypass Surgery versus AngioplasTy Using Drug-Eluting Stent in Patients with Left Main Coronary Artery Disease] study) treated between July 2007 and July 2015, the authors identified 2,692 patients with significant LMCAD who received second-generation DES; 1,254 with cobalt-chromium everolimus-eluting stents (CoCr-EES), 232 with biodegradable polymer biolimus-eluting stents (BP-BES), 616 with platinum-chromium EES (PtCr-EES), and 590 with Resolute zotarolimus-eluting stent (Re-ZES). The primary outcome was target-vessel failure. RESULTS: The observed 3-year rates of target-vessel failure were not significantly different for the different types of DES (16.7% for the CoCr-EES, 13.2% for the BP-BES, 18.7% for the PtCr-EES, and 14.7% for the Re-ZES; p = 0.15). In multiple treatment propensity score analysis, the adjusted hazard ratios (HRs) for target-vessel failure were similar in between-group comparisons of the different DES, except for the PtCr-EES versus the BP-BES (reference; HR: 1.60; 95% confidence interval: 1.01 to 2.54; p = 0.046). There were no significant differences in risk of composite of all-cause death, any myocardial infarction, or any revascularization and its individual components according to the different types of DES. Although the 3-year incidence of stent thrombosis was considerably low (≤1.0%) for all types of DES, between-group differences were observed, generally favoring the EES platforms. CONCLUSIONS: In this pooled analysis of 3 prospective registries involving unrestricted use of various second-generation DES for LMCAD, we found no significant between-group differences in 3-year risk of target-vessel failure, except for a higher risk of primary outcome with PtCr-EES compared to BP-BES. (Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical Practice [IRIS-DES]; NCT01186133).
引用
- Lee PH, Kwon O, Ahn JM, et al. Safety and Effectiveness of Second-Generation Drug-Eluting Stents in Patients With Left Main Coronary Artery Disease. J Am Coll Cardiol. 2018. PMID: 29471933. doi:10.1016/j.jacc.2017.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。